FindTrial
Sign In

This study examines Program death ligands-1 expression in head and neck cancer and its link to tumour size, stage and other clinical features.

Programmed Death-Ligand 1 Expression in Primary Head and Neck Squamous cell carcinoma(HNSCC) and its association with clinicopathological variables - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/04/085304
Enrollment
40
Registered
2025-04-22
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynx

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Dr Mansi Mishra
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All consecutively diagnosed cases of HNSCC either on biopsy or surgical resected received in Department of Pathology, GMC Haldwani.

Exclusion criteria

Exclusion criteria: Patient not willing to be part of study Reference slide from outside GMC Haldwani Metastatic cases of Head and Neck Squamous cell carcinoma. HNSCC cases who have recieved previous Chemotherapy

Design outcomes

Primary

MeasureTime frame
To evaluate the expression of PDL1 in Head and neck Squamous cell carcinoma patient.Timepoint: 18 months—

Secondary

MeasureTime frame
To determine its association with clinicopathological variables (age, gender, site of tumour, histological grade of tumour, Stage of tumour, mitotic index & lymphovascular invasion) in HNSCC patientsTimepoint: 18 months—

Countries

India

Contacts

Public ContactDr Hari Shankar Pandey

Government Medical College, Haldwani.

physianin@gmail.com9305686692

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026